TScan Therapeutics, Inc.
NASDAQ:TCRX
2.63 (USD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.049 | 0.536 | 0.566 | 7.211 | 3.887 | 3.148 | 6.803 | 0.001 | 3.363 | 4.056 | 3.021 | 2.854 | 2.412 | 2.848 | 2.027 | 0.795 | 0.29 | 0 | 0 |
| Cost of Revenue
| 0 | 1.116 | 1.254 | 1.28 | 1.286 | 1.296 | 1.499 | 1.484 | 0 | 1.207 | 1.195 | 1.142 | 14.206 | 10.801 | 7.339 | 5.964 | 5.813 | 4.502 | 4.298 |
| Gross Profit
| 1.049 | -0.58 | -0.688 | 5.931 | 2.601 | 1.852 | 5.304 | -1.483 | 3.363 | 2.849 | 1.826 | 1.712 | -11.794 | -7.953 | -5.312 | -5.169 | -5.523 | -4.502 | -4.298 |
| Gross Profit Ratio
| 1 | -1.082 | -1.216 | 0.822 | 0.669 | 0.588 | 0.78 | -1,483 | 1 | 0.702 | 0.604 | 0.6 | -4.89 | -2.792 | -2.621 | -6.502 | -19.045 | 0 | 0 |
| Reseach & Development Expenses
| 26.262 | 26.877 | 24.857 | 22.406 | 22.741 | 21.227 | 21.779 | 15.604 | 15.031 | 14.494 | 14.69 | 12.608 | 14.206 | 10.801 | 7.339 | 5.964 | 5.813 | 4.502 | 4.298 |
| General & Administrative Expenses
| 7.409 | 7.773 | 7.082 | 6.162 | 5.894 | 6.531 | 7.767 | 6.14 | 4.91 | 4.808 | 4.494 | 4.448 | 4.048 | 2.726 | 2.606 | 2.641 | 1.648 | 1.114 | 1.338 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | -1.28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 7.409 | 7.773 | 7.082 | 4.882 | 5.894 | 6.531 | 7.767 | 6.14 | 4.91 | 4.808 | 4.494 | 4.448 | 4.048 | 2.726 | 2.606 | 2.641 | 1.648 | 1.114 | 1.338 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.9 | 0 | 0 | 0.007 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 33.671 | 34.65 | 31.939 | 27.288 | 28.635 | 27.758 | 29.546 | 21.744 | 19.941 | 19.302 | 19.184 | 17.056 | 18.254 | 13.527 | 9.945 | 8.605 | 7.461 | 5.616 | 5.636 |
| Operating Income
| -32.622 | -34.114 | -31.373 | -21.357 | -24.748 | -24.61 | -22.743 | -18.648 | -16.578 | -15.246 | -16.149 | -14.202 | -15.842 | -10.679 | -7.918 | -7.81 | -7.171 | -5.616 | -5.636 |
| Operating Income Ratio
| -31.098 | -63.646 | -55.429 | -2.962 | -6.367 | -7.818 | -3.343 | -18,648 | -4.93 | -3.759 | -5.346 | -4.976 | -6.568 | -3.75 | -3.906 | -9.824 | -24.728 | 0 | 0 |
| Total Other Income Expenses Net
| 2.735 | 2.453 | 1.231 | 1.744 | 1.751 | 0.565 | 0.18 | -0.074 | 0.333 | 0.149 | 0.007 | 0.002 | 0.003 | 0.005 | 0.006 | 0.003 | 0.001 | 0.003 | 0.099 |
| Income Before Tax
| -29.887 | -31.661 | -30.142 | -19.613 | -22.997 | -24.045 | -22.563 | -18.723 | -16.245 | -15.097 | -16.156 | -14.2 | -15.839 | -10.674 | -7.912 | -7.807 | -7.17 | -5.613 | -5.537 |
| Income Before Tax Ratio
| -28.491 | -59.069 | -53.254 | -2.72 | -5.916 | -7.638 | -3.317 | -18,723 | -4.831 | -3.722 | -5.348 | -4.975 | -6.567 | -3.748 | -3.903 | -9.82 | -24.724 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -1.254 | -1.024 | -1.286 | 1.534 | 1.094 | 0.074 | 0.534 | -0.149 | -0.007 | -0.002 | -0.003 | -0.005 | -0.006 | -0.006 | -0.001 | -0.003 | -0.099 |
| Net Income
| -29.887 | -31.661 | -30.142 | -19.613 | -22.997 | -24.045 | -22.563 | -18.797 | -16.245 | -14.948 | -16.149 | -14.2 | -15.839 | -10.674 | -7.912 | -7.807 | -7.17 | -5.613 | -5.537 |
| Net Income Ratio
| -28.491 | -59.069 | -53.254 | -2.72 | -5.916 | -7.638 | -3.317 | -18,797 | -4.831 | -3.685 | -5.346 | -4.975 | -6.567 | -3.748 | -3.903 | -9.82 | -24.724 | 0 | 0 |
| EPS
| -0.25 | -0.28 | -0.32 | -0.21 | -0.24 | -0.51 | -0.93 | -0.78 | -0.67 | -0.62 | -0.67 | -0.59 | -0.67 | -0.45 | -0.32 | -0.33 | -0.3 | -0.23 | -0.23 |
| EPS Diluted
| -0.25 | -0.28 | -0.32 | -0.21 | -0.24 | -0.51 | -0.93 | -0.78 | -0.67 | -0.62 | -0.67 | -0.59 | -0.67 | -0.45 | -0.32 | -0.33 | -0.3 | -0.23 | -0.23 |
| EBITDA
| -27.902 | -29.593 | -27.929 | -17.481 | -20.729 | -21.78 | -20.108 | -16.264 | -14.793 | -13.89 | -14.961 | -13.06 | -14.783 | -10.018 | -7.449 | -7.414 | -6.825 | -5.35 | -5.414 |
| EBITDA Ratio
| -26.599 | -55.211 | -55.429 | -2.784 | -6.367 | -6.919 | -3.176 | -17,748 | -4.399 | -3.461 | -5.35 | -4.576 | -6.13 | -3.518 | -3.675 | -9.326 | -23.534 | 0 | 0 |